Moderna's mRNA Flu Vaccine Faces FDA Scrutiny

Moderna’s mRNA flu vaccine, mFlusiva, is poised to shake up flu season—designed for seniors, it could be faster and more adaptable than traditional shots. After a rocky start with FDA pushback over comparison studies, Moderna’s data now shows antibody levels rivaling high-dose vaccines. The FDA advisory panel’s vote this week could decide if this game-changing tech finally gets the green light—especially for vulnerable older adults. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/813bc8cc7a526d00